Biostar Pharmaceuticals, Inc. Announces Opening of a Sales Office in Gansu Province, PRC

  Biostar Pharmaceuticals, Inc. Announces Opening of a Sales Office in Gansu
                                Province, PRC

Anticipated Revenue of USD $4 million in 2014

PR Newswire

XIANYANG, China, Jan. 10, 2014

XIANYANG, China, Jan. 10, 2014 /PRNewswire/ -- Biostar Pharmaceuticals, Inc.
(NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and
marketer of pharmaceutical and health supplement products in China for a
variety of diseases and conditions, today announced the Company had
established an office in Gansu Province, PRC, on January 6, 2014 with the
focus on the sales of Hepatitis B products in three provinces, including
Gansu, Qinghai and Tibet. These three provinces are located in the western
region of China where pharmaceutical products historically have shown a
consistently good sales track record primarily due to the relatively poor
medical condition and corresponding high incidence of Hepatitis B among the
residents of these provinces. With the ongoing expansion of the national
health care reform, the Company established Gansu sales office to extend its
sales effort to these provinces and to expand the Company's market share,
which efforts mark the commencement of the Company's major marketing
initiative in 2014.The Company expects that in 2014, this newly opened sales
office will contribute USD$4 million additional revenue of the Company. The
marketing and administrative personnel are currently onsite undergoing

Mr. Ronghua Wang, the CEO of the Company stated that "although the 2012
capsule related events adversely affect our markets, after eighteen months, we
observe market recovery and our sales of Hepatitis B products are now in line
with our expectations. We established this new sales office to continue with
our product sales expansion. In addition, we intend to establish an Inner
Mongolia office to carry on with the product sales in Inner Mongolia and
Ningxia after the Chinese New Year. Once that is completed, our product sale
efforts will cover the entire country," he concluded.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and
controlled affiliate in China, develops, manufactures and markets
pharmaceutical and health supplement products for a variety of diseases and
conditions.The Company's most popular product is its Xin Aoxing Oleanolic
Acid Capsule, an over-the-counter ("OTC") medicine for chronic Hepatitis B, a
disease affecting approximately 10% of the Chinese population. For more
information please visit:

Safe Harbor Relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are
forward-looking statements, within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended, which involve a number of risks and
uncertainties that could cause actual results to differ materially from those
in such forward-looking statements. The company uses words and phrases such as
"guidance," "forecasted," "projects," "is expected," "remain confident,"
"will" and similar expressions to identify forward-looking statements in this
press release, including forward-looking statements. Undue reliance should not
be placed on forward-looking information. Forward-looking information is based
on current expectations, estimates and projections that involve a number of
risks, which could cause actual results to vary and in some instances to
differ materially from those anticipated by Biostar and described in the
forward-looking information contained in this news release. The risks and
uncertainties relating to these statements include, but are not limited to,
risks and uncertainties regarding the Company's ability to achieve the
projected sales in the recently opened sales offices, to complete the
contemplated clinical trials and capitalize on such opportunities, the
Company's ability to recover its sales and revenue for the gel capsule segment
of its business, the state of consumer confidence and market demand or the
Company's products, success of our investments, risks and uncertainties
regarding fluctuations in earnings, our ability to sustain our previous levels
of profitability including on account of our ability to manage growth, intense
competition, wage increases in China, our ability to attract and retain highly
skilled professionals, time and cost overruns on fixed-price, fixed-time frame
contracts, client concentration, our ability to successfully complete and
integrate potential acquisitions, withdrawal of governmental fiscal
incentives, political instability and regional conflicts and legal
restrictions on raising capital or acquiring companies outside China.
Additional risks that could affect our future operating results are more fully
described in our United States Securities and Exchange Commission filings
including our most recent Annual Report on Form 10-K for the year ended
December 31, 2012, and other subsequent filings. These filings are available We may, from time to time, make additional written and oral
forward-looking statements, including statements contained in our filings with
the Securities and Exchange Commission and our reports to shareholders. We do
not undertake to update any forward-looking statements that may be made from
time to time by or on our behalf.

For more information contact:

Biostar Pharmaceuticals, Inc. Inc
Ally Gong                      Alice
Tel: +86-29-3368-6638          Tel: +86-4001200987
Email: Email:

SOURCE Biostar Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.